Scarica l'app Stockscreener
6.195
8.12%
0.465
Dopo l'orario di chiusura:
6.17
-0.025
-0.40%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VERV Giù?
Forum
Previsione
Precedente Chiudi:
$5.73
Aprire:
$5.85
Volume 24 ore:
4.67M
Relative Volume:
1.42
Capitalizzazione di mercato:
$396.69M
Reddito:
$20.65M
Utile/perdita netta:
$-192.65M
Rapporto P/E:
-2.3919
EPS:
-2.59
Flusso di cassa netto:
$-134.39M
1 W Prestazione:
+39.21%
1M Prestazione:
+42.09%
6M Prestazione:
-4.25%
1 anno Prestazione:
+17.33%
Intervallo 1D:
$5.772
$6.58
Intervallo di 1 settimana:
$4.50
$6.58
Portata 52W:
$2.8647
$9.305
Verve Therapeutics Inc Stock (VERV) Company Profile
Nome
Verve Therapeutics Inc
Settore
Industria
Telefono
(978) 501-3026
Indirizzo
201 BROOKLINE AVENUE, BOSTON
Confronta VERV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VERV
Verve Therapeutics Inc
|
6.195 | 396.69M | 20.65M | -192.65M | -134.39M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-04-08 | Iniziato | H.C. Wainwright | Buy |
| 2023-04-13 | Iniziato | Canaccord Genuity | Buy |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-12-15 | Iniziato | Goldman | Sell |
| 2022-10-06 | Iniziato | Credit Suisse | Neutral |
| 2022-08-25 | Aggiornamento | Stifel | Hold → Buy |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-02-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-09-24 | Iniziato | Stifel | Hold |
| 2021-07-12 | Iniziato | Guggenheim | Buy |
| 2021-07-12 | Iniziato | JP Morgan | Neutral |
| 2021-07-12 | Iniziato | Jefferies | Buy |
| 2021-07-12 | Iniziato | William Blair | Outperform |
Mostra tutto
Verve Therapeutics Inc Borsa (VERV) Ultime notizie
Lost Money on Verve Therapeutics, Inc.(VERV)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Transcript : Verve Therapeutics, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 09 - marketscreener.com
Verve Therapeutics (VERV) Just Reclaimed the 200-Day Moving Average - Yahoo Finance
Wall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High? - Yahoo Finance
BNP Paribas Financial Markets Purchases Shares of 8,876 Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Acquired by ProShare Advisors LLC - Defense World
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Verve Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule - marketscreener.com
Verve Therapeutics Grants Equity Awards to New Employees as Part of Inducement Stock Incentive Plan - Nasdaq
Latest Employee Stock Grants: Verve Therapeutics Issues 87,000 Shares Worth of Equity Awards - Stock Titan
Bank of America Corp DE Reduces Position in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Acquired by Ameriprise Financial Inc. - Defense World
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Deutsche Bank AG - Defense World
Nuveen Asset Management LLC Sells 355,953 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
37,984 Shares in Verve Therapeutics, Inc. (NASDAQ:VERV) Acquired by D. E. Shaw & Co. Inc. - Defense World
Verve Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationVERV - ACCESS Newswire
Canaccord Genuity Reaffirms Their Buy Rating on Verve Therapeutics (VERV) - The Globe and Mail
Verve Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely - simplywall.st
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Acquired by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Verve Therapeutics (NASDAQ:VERV) Upgraded at Wall Street Zen - Defense World
Northern Trust Corp Raises Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Transcript : Verve Therapeutics, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-21-2025 03 - marketscreener.com
Analysts Offer Predictions for VERV FY2026 Earnings - Defense World
3 Top Genomics Stocks to Add to Your Portfolio in 2025 - Yahoo Finance
Verve Therapeutics Leads The Charge With 2 Other Promising Penny Stocks - simplywall.st
Bio/Pharmaceutical Outsourcing Report, March 2025 Edition - GlobeNewswire Inc.
News Flash: Analysts Just Made An Incredible Upgrade To Their Verve Therapeutics, Inc. (NASDAQ:VERV) Forecasts - simplywall.st
Analyst Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher - Yahoo Finance
Cantor Fitzgerald Issues Positive Outlook for VERV Earnings - Defense World
Price T Rowe Associates Inc. MD Lowers Position in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Brokerages Set Verve Therapeutics, Inc. (NASDAQ:VERV) PT at $25.75 - Defense World
Analysts Offer Insights on Healthcare Companies: Verve Therapeutics (VERV), Nkarta (NKTX) and Kamada (KMDA) - The Globe and Mail
Dimensional Fund Advisors LP Raises Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Verve Therapeutics: Q1 Earnings Snapshot - CT Insider
Verve Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results - GlobeNewswire
Verve Therapeutics (VERV) Beats Q1 EPS Estimates, Reports Signif - GuruFocus
Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Verve Therapeutics (VERV) Exceeds Revenue Estimates and Advances - GuruFocus
Verve Therapeutics, Inc. SEC 10-Q Report - TradingView
Verve Therapeutics (VERV) Exceeds Revenue Estimates and Advances Clinical Trials | VERV Stock News - GuruFocus
Verve Therapeutics (VERV) Projected to Post Quarterly Earnings on Wednesday - Defense World
Stifel Financial Corp Purchases 9,736 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Tower Research Capital LLC TRC Lowers Stock Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street - AOL.com
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Verve Therapeutics Inc Azioni (VERV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.21%
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):